Goldman Sachs Group Inc. Acquires 119,145 Shares of Replimune Group, Inc. $REPL

Key Points

• Goldman Sachs Group Inc. increased its stake in Replimune Group, Inc. by 20.9%, acquiring 119,145 shares, giving it ownership of approximately 0.90% of the company valued at $6.7 million.
• Analysts have recently downgraded the stock with BMO Capital Markets slashing its price target from $27 to $2, while others like JPMorgan and Wedbush have also reduced their ratings.
• Replimune Group reported a loss of ($0.95) EPS for the last quarter, missing estimates by $0.12, contributing to bearish sentiment among analysts.

Goldman Sachs Group Inc. boosted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 20.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 690,167 shares of the company's stock after purchasing an additional 119,145 shares during the period. Goldman Sachs Group Inc. owned about 0.90% of Replimune Group worth $6,729,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of REPL. Tang Capital Management LLC increased its holdings in Replimune Group by 125.0% during the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock valued at $32,697,000 after purchasing an additional 1,500,000 shares during the period. Wellington Management Group LLP boosted its position in Replimune Group by 352.5% during the 4th quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock valued at $13,282,000 after acquiring an additional 854,346 shares in the last quarter. Nuveen LLC bought a new stake in Replimune Group during the 1st quarter valued at approximately $6,546,000. Woodline Partners LP boosted its position in Replimune Group by 156.6% during the 4th quarter. Woodline Partners LP now owns 854,309 shares of the company's stock valued at $10,346,000 after acquiring an additional 521,366 shares in the last quarter. Finally, Nuveen Asset Management LLC boosted its position in Replimune Group by 108.9% during the 4th quarter. Nuveen Asset Management LLC now owns 667,634 shares of the company's stock valued at $8,085,000 after acquiring an additional 347,993 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 9,154 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the transaction, the chief financial officer owned 134,368 shares of the company's stock, valued at $721,556.16. This represents a 6.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

REPL has been the topic of several research reports. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of Replimune Group in a research report on Friday. Leerink Partnrs cut Replimune Group from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 22nd. Wedbush reaffirmed a "neutral" rating and set a $4.00 price objective (down from $19.00) on shares of Replimune Group in a research report on Tuesday, July 22nd. Jefferies Financial Group cut their price objective on Replimune Group from $31.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Finally, HC Wainwright reissued a "neutral" rating on shares of Replimune Group in a research report on Monday, September 8th. Two equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $6.50.

Replimune Group Price Performance

REPL stock traded down $0.09 during trading on Friday, reaching $3.38. The company's stock had a trading volume of 4,219,345 shares, compared to its average volume of 4,022,004. Replimune Group, Inc. has a 1 year low of $2.68 and a 1 year high of $17.00. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $263.44 million, a P/E ratio of -1.04 and a beta of 0.51. The company's fifty day moving average is $6.29 and its 200-day moving average is $8.27.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). On average, research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.